Login to Your Account



Medarex Moves Lead Antibody Into Front-Line Phase III Study

By Aaron Lorenzo


Tuesday, June 20, 2006
Medarex Inc. is pushing its targeted cancer therapy, ipilimumab, into a registrational trial for untreated metastatic melanoma patients after receiving a special protocol assessment from the FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription